Design and characterization of broadly protective influenza A(H3N2) vaccine candidates using protein language models
Howard, V. R.; Allen, J. D.; Thomas, M. H.; Sautto, G. A.; Ross, T. M.; Georgiev, I. S.
Show abstract
Seasonal influenza A viruses cause significant global morbidity each year. Although vaccination remains the primary preventive strategy, effectiveness is often reduced by antigenic drift. This challenge is particularly pronounced for influenza A(H3N2), which has required eight vaccine updates over the past decade. Here, we present a computational framework to engineer broadly reactive influenza A(H3N2) vaccines, using protein language models to generate novel hemagglutinin (HA) sequences and a machine learning model to predict antigenic distance from circulating strains. In a proof-of-concept study, seven HA candidates designed using sequence data from 2013-2018 were evaluated in mice against contemporary and subsequently circulating viruses. Two candidates elicited protective levels of reactive antibodies, robust H3-specific antibody-secreting cell responses, and cross-neutralization against contemporary clades and drifted 2019-2020 strains. These findings demonstrate that an integrated generation-selection strategy can enhance vaccine coverage across current and future A(H3N2) seasons and may be applicable to other influenza subtypes.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Molecular engineering of a cryptic epitope in Spike RBD improves manufacturability and neutralizing breadth against SARS-CoV-2 variants 93%
- Post-vaccine HAI antibody kinetics are driven by pre-vaccination HAI titre and vaccine history 93%
- Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice 92%
Similar papers in this journal
- A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta 93%
- Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants 92%
- CD8+ T cell cross-reactivity against SARS-CoV-2 conferred by other coronavirus strains and influenza virus 92%
Similar papers in this journal
- Single-dose avian influenza A(H5N1) Clade 2.3.4.4b hemagglutinin-Matrix-M nanoparticle vaccine induces neutralizing responses in nonhuman primates 94%
- Epigraph Hemagglutinin Vaccine Induces Broad Cross-reactive Immunity Against Swine H3 Influenza Virus 94%
- Antigenic assessment of the H3N2 component of the 2019-2020 Northern Hemisphere influenza vaccine 94%
Similar papers in this journal
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.